Fulvestrant Injection, Solution
NDC Package 70771-1626-8

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Fulvestrant injection is fulvestrant is used to treat certain types of breast cancer. This formulation utilizes a injection, solution delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 70771-1626 and is authorized under FDA application ANDA215234.

Identification & Billing

NDC Package Code
70771-1626-8
Package Description
2 SYRINGE, GLASS in 1 CARTON / 5 mL in 1 SYRINGE, GLASS (70771-1626-2)
Product Code
70771-1626
11-Digit Billing Format
70771162608
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Fulvestrant
Non-Proprietary Name
Fulvestrant
Substance Name
Fulvestrant
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
FULVESTRANT 50 mg/mL
Pharmacologic Class
Usage Information
Fulvestrant is used to treat certain types of breast cancer. Breast cancer cells need the hormone estrogen in order to grow. Fulvestrant works by blocking the effect of estrogen, slowing tumor cell growth.

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA215234
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-14-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70771-1626-8 identifies a specific commercial package of 2 syringe, glass in 1 carton / 5 ml in 1 syringe, glass (70771-1626-2) of Fulvestrant, a human prescription drug labeled by Zydus Lifesciences Limited. This injection, solution is formulated for intramuscular use and contains fulvestrant as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on December 14, 2021. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Fulvestrant is used to treat certain types of breast cancer. Breast cancer cells need the hormone estrogen in order to grow. Fulvestrant works by blocking the effect of estrogen, slowing tumor cell growth.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771162608. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70771-1626-8
11-Digit CMS (5-4-2)
70771-1626-08

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.